The universe of arachidonic acid metabolites in inflammatory bowel disease: Can we tell the good from the bad?

Current Opinion in Gastroenterology

Volumn 30, Issue 4, 2014, Pages 347-351

  Stenson, William F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Crohn's disease; Cyclooxygenase; Hepoxilin A3; Prostaglandins; Ulcerative colitis

Indexed keywords

ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DRUG METABOLITE; HEPOXILIN A; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 8; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN G2; PROSTAGLANDIN H2; SUPPRESSOR OF CYTOKINE SIGNALING 1; THROMBOXANE A2; TUMOR NECROSIS FACTOR ALPHA; 8-HYDROXY-11,12-EPOXYEICOSA-5,9,14-TRIENOIC ACID; ANTIINFLAMMATORY AGENT; DIHOMO GAMMA LINOLENIC ACID;

ARACHIDONIC ACID METABOLISM; CELL MIGRATION; CROHN DISEASE; DENDRITIC CELL; ENDOTHELIUM CELL; EPITHELIUM CELL; GASTROINTESTINAL MUCOSA; HISTOLOGY; HOMEOSTASIS; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INFLAMMATORY BOWEL DISEASE; MACROPHAGE; MESENCHYMAL STEM CELL; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TH17 CELL; ULCERATIVE COLITIS; ANALOGS AND DERIVATIVES; CELL MOTION; HUMAN; IMMUNOLOGY; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; METABOLISM; PATHOPHYSIOLOGY;

8,11,14-EICOSATRIENOIC ACID; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; CELL MOVEMENT; DINOPROSTONE; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; NEUTROPHILS; PROSTAGLANDIN D2; SIGNAL TRANSDUCTION; TH17 CELLS;

EID: 84902261222     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000075     Document Type: Review

References (32)

1. Eberhart CE, Dubois RN. Eicosanoids and the gastrointestinal tract. Gastroenterology 1995; 109:285-301.
2. Felder JB, Korelitz BI, Rajapakse R, et al. Effects of nonsteroidal anti-inflammatory drugs on inflammatory bowel disease: A case-control study. Am J Gastroenterol 2000; 95:1949-1954.
3. Brown SL, Riehl TE, Walker MR, et al. Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury. J Clin Invest 2007; 117:258-269.
4. Herschman HR. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev 1994; 13:241-256.
5. McCartney SA, Mitchell JA, Fairclough PD, et al. Selective COX-2 inhibitors and human inflammatory bowel disease. Aliment Pharmacol Ther 1999; 13:1115-1117.
6. Reuter BK, Asfah S, Buret A, et al. Exacerbation of inflammation- associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 1996; 98:2076-2085.
7. Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: A randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006; 4:203-211.
8. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247-1255.
9. Vong L, Ferraz J, Panaccione R, et al. A pro-resolution mediator, prostaglandin D2, is specifically up-regulated in individuals in long-term remission from ulcerative colitis. PNAS 2010; 107:12023-12027.
10. Laursen LS, Lauritsen K, Bukhave K, et al. Selective 5-lipoxygenase inhibition by zileuton in the treatment of relapsing ulcerative colitis: A randomized double-blind placebo-controlled multicenter trial. Eur J Gastro and Hepato 1994; 6:209-215.
11. Mrsny RJ, Gewirtz AT, Siccardi D, et al. Indentification of hepoxilin A3 in inflammatory events: A required role in neutrophil migration across intestinal epithelia. Proc Natl Acad Sci 2004; 101:7421-7426.
12. Chinen T, Komai K, Muto G, et al. Prostaglandin E2 and SOCS1 have a role in intestinal immune tolerance. Nat Commun 2011; 2:190.
13. Fukata M, Chen A, Klepper A, et al. COX-2 is regulated by toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology 2006; 131:862-877.
14. Khare BA, Zhang HM, Barmada MM, et al. Prostaglandin E2 and IL-23 plus IL-1 beta differentially regulate the Th1/Th17 immune response of human CD161 (þ) CD4(þ) memory T cells. Clin Transl Sci 2001; 4:268-273.
15. Winer S, Paltser G, Chan Y, et al. Obesity predisposes to Th17 bias. Eur J Immunol 2009; 39:2629-2635.
16. Sheibanie AF, Yen JH, Khayrullina T, et al. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23!IL-17 axis. J Immunol 2007; 178:8138-8147.
17. Boniface K, Bak-Jensen KS, Li Y, et al. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. JEM 2009; 206:535-548.
18. Ajuebor MN, Singh A, Wallace JL. Cyclooxygenase-2 derived prostaglandin D2 is an early anti-inflammatory signal in experimental colitis. Am J Physiol Gastrointest Liver Physiol 2000; 279:G238-G244.
19. Gilroy DW, Colville-Nash PR, Wilis J, et al. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999; 5:698-701.
20. Rajakariar R, Hilliard M, Lawrence T, et al. Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. Proc Natl Acad Sci USA 2007; 104:20979-20984.
21. Zamuner SR, Warrier N, Buret AG, et al. Cyclooxygenase 2 mediates postinflammatory colonic secretory and barrier dysfunction. Gut 2003; 52:1714-1720.
22. Zamuner SR, Bak AW, Devchand PR, Wallace JL. Predispostion to colorectal cancer in rats with resolved colitis; role of cyclooxygenase-2 derived prostaglandin D2. Am J Pathol 2005; 167:1293-1300.
23. Hokari R, Kurihara C, Nagata N, et al. Increased expression of lipocalin-typeprostaglandin D synthase in ulcerative colitis and exacerbating role in murine colitis. Am J Physiol Gastrointest Liver Physuiol 2011; 300:G401-G408.
24. Singer II, Kawka DW, Schloemann S, et al. Cyclooxygenase-2 induced in colonic epithelia cells in inflammatory bowel disease. Gastro 1998; 115:297-306.
25. Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4:196-202.
26. Meyer AM, Ramzan NH, Heigh RI, Leighton JA. Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs. Dig Dis Sci 2006; 51:168-172.
27. Evans JM, McMahon AD, Murray FE, et al. Nonsteroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. GUT 1997; 40:619-622.
28. Kucharzik T, Hudson JT 3rd, Lugering A, et al. Acute induction of human IL-8 production by intestinal epithelium triggers neutrophil infiltration without mucosal injury. Gut 2005; 54:1565-1572.
29. Stenson WF, Prescott SM, Sprecher H. Leukotriene B formation by neutrophils from essential fatty acid deficient rats. J Biol Chem 1994; 259:11784.
30. Sharon P, Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984; 86:453.
31. McCormick BA, Hofman PM, Kim J, et al. Surface attachment of salmonella typhimurium to intestinal epithelia imprints the subepithelial matrix with gradients chemotactic for meutrophils. J Cell Biol 1995; 131:1599-1608.
32. Shannon VR, Stenson WF, Holtzman MJ. Induction of epithelial arachidonate 12-lipoxygenase at active sites of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 1993; 264:G104-G111.